/
Other
Atrophy
60
Pipeline Programs↗
115
Active Trials↗
67
Companies Involved↗
Atrophy is a moderately active landscape with 60 programs across 67 companies. The most active players are Roche. 11 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical17
Phase 113
Phase 219
Phase 311
Approved
No programs
Analysis
Modality Breakdown
84%
Small molecule
37 of 44 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 44 classified programs, each share of the total. Modality classified for 85% of 60 pipeline programs.
Analysis
Trial Status
305
clinical trials
Completed145 · 48%
Recruiting60 · 20%
Active, not recruiting32 · 10%
Terminated24 · 8%
Not yet recruiting19 · 6%
Withdrawn8 · 3%
Other17 · 6%
Clinical Trials
Trial Activity
305 trials
Page 1 of 21
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)